GSK-189254

GSK-189254

GSK-189254 is a drug developed by GlaxoSmithKline that acts as a potent and selective H3 receptor antagonist. The H3 receptor is a G protein-coupled receptor that is found primarily in the central nervous system and plays a role in a variety of neurological functions.

Pharmacology

GSK-189254 has been shown to increase wakefulness and cognitive function in animal models. It is thought to work by blocking the action of histamine at the H3 receptor, thereby increasing the release of neurotransmitters such as acetylcholine and dopamine. This can lead to increased arousal and improved cognitive function.

Clinical Trials

GSK-189254 has undergone Phase I clinical trials for the treatment of Alzheimer's disease and narcolepsy. However, the results of these trials have not been published, and it is unclear whether the drug will be further developed for these indications.

Side Effects

As with any drug, GSK-189254 has the potential to cause side effects. These may include nausea, headache, and insomnia. However, the frequency and severity of these side effects are not known, as the drug has not been extensively tested in humans.

See Also

• H3 receptor
• GlaxoSmithKline
• Alzheimer's disease
• Narcolepsy

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!